TNFRSF8 and lymphoma: Herein, in this study, we performed a combinatorial strategy with anti-PD-1 and anti-CD30 CAR-T cell treatment in patients with r/r CD30+ lymphomas and showed a synergetic anti-tumor activity of immune checkpoint inhibitor with minimal toxicities.